Flu vaccine contracts
Five drug manufacturers received five-year contracts totaling roughly $1 bil. to accelerate development and production of new cell-based vaccine technologies within the U.S., HHS announces May 4. Solvay received the largest contract ($298.6 mil.) to develop and test vaccines, as well as to develop a master plan to manufacture, formulate, fill and package annual and pandemic vaccines. GlaxoSmithKline received $274.8 mil. for clinical programs for a trivalent seasonal flu vaccine and an H5N1 vaccine. Novartis received $220.5 mil. to augment vaccine research efforts and to aid in establishing a U.S.-based vaccine manufacturing facility. MedImmune received $169.5 mil. to develop cell-based seasonal and pandemic vaccines using technology underlying FluMist. Computer Sciences Corp.'s DynPort Vaccine Co., which is working with Baxter on seasonal and pandemic vaccines, also received an incremental award of $41 mil. toward a pending $242.6 mil. contract...
You may also be interested in...
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
The leadership of top Indian firms recounted at the IPA Forum how they got together on a joint 45-minute call daily in the early phase of the pandemic to collaborate and ensure uninterrupted supplies of medicines both in India and globally. The executives also shared views on telemedicine and digitalization trends at the event.